Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
About the study
The main purpose of this study is to investigate the effectiveness of cladribine tablets in a UK real-world setting.
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Physician diagnosis of HDA-RRMS as defined by clinical or radiological features
- Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and at least 3 years before enrolment
- Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per recommended dose in Year 1: 1.75 milligrams per kilogram [mg/kg] body weight, cumulatively)
EXCLUSION CRITERIA
Exclusion Criteria:
- Received cladribine tablet treatment within an interventional clinical trial during the study period
- Received treatment with any investigational therapy for RRMS in the 6 months prior to cladribine tablet treatment initiation
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Relapsing-Remitting Multiple Sclerosis
Age (in years)
18+
Participants needed
116
Est. Completion Date
Oct 27, 2023
Treatment type
Observational
Sponsor
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
ClinicalTrials.gov identifier
NCT04997148
Study number
MS700568-0150
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?